Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

NCT01488318 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

OTHER

Sponsor class

Stopped PI leaving the institution

Conditions

Squamous Cell Carcinoma Of The Head And Neck

Interventions

DRUG: Cetuximab
DRUG: Dasatinib

Sponsor

Julie E. Bauman, MD, MPH

Collaborators

[object Object]